% | $
Quotes you view appear here for quick access.

Oramed Pharmaceuticals Inc. Message Board

assted 32 posts  |  Last Activity: Jun 1, 2015 10:08 AM Member since: Mar 2, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • assted assted Jun 1, 2015 10:08 AM Flag

    Keep your pants on. All the biotechs are in a "buy the rumor, sell the news" mode which was clearly predicable considering the pre-meeting run up.

  • Reply to

    Why Worry?

    by sixman02 May 5, 2015 7:40 PM
    assted assted May 6, 2015 1:17 PM Flag

    Yes, I am ignorant. But I cashed out with a 15 point profit (admittedly a long term hold) while you're still waiting for the tooth fairy.

  • Reply to

    Why Worry?

    by sixman02 May 5, 2015 7:40 PM
    assted assted May 6, 2015 11:37 AM Flag

    Yes, especially when they think the price will go up.

  • Reply to

    Not the message I was hoping for

    by assted May 5, 2015 2:17 PM
    assted assted May 5, 2015 2:27 PM Flag

    200,000 out of 600,000. I was looking to get back in but this makes me very nervous.

  • This is not good news. The President and COO sold 1/3 of his position after last week's quarterly report. Yahoo will not let me post the link, but you can find it by going to the VDSI page on, and click on "SEC filings" in the left column. When you're on the SEC filings page, it's the 2nd one listed (form type 4).

  • ...and begging for an intelligent, non-sarcastic answer:

    Why does the company seem to have difficulty cracking the US market? Is it because the US still uses the old magnetic strip credit cards while the rest of the world is moving to chip on a card? If so, once the US finally moves to chip on a card, it should be a bonanza for VDSI.

  • Reply to

    Great report, but...

    by assted Apr 28, 2015 7:52 AM
    assted assted Apr 28, 2015 8:07 AM Flag

    No specific target. There will be an early pop today and if it starts to fade I'll punch my ticket. I'm fortunate to have bought long ago in the single digits so I'm not going quibble on the exit price. I do admit I think this company will eventually be acquired so I'm concerned about missing that but I'm still inclined to take the money and run.

  • ...a few warnings signs:

    1. Dependence on single customer: "Revenues related to our delivery of all products sold to Rabobank globally exceeded 30% of the first quarter's revenue."

    2. Forward guidance: "We expect that comparisons of 2015 results to the prior year will be stronger in the first half of this year than in the second half."

    No, I am not short and have been long for ~ 5 years, but I will be looking for the exit door over the next few days.

  • Halozyme Therapeutics (HALO) Bullish Stance Reiterated at BMO Capital Amid Positive AACR Update
    7:51 AM ET, 04/20/2015 - StreetInsider
    BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $26 price target on Halozyme Therapeutics (NASDAQ: HALO) after the American Association of Cancer Research meeting where, over the weekend, Halozyme PEGPH20 investigator, Dr. Sunil Hingorani discussed the targeting of hyaluronan (HA) in pancreatic cancer, noting that PEGPH20 combined with chemotherapy results in permanent favorable architectural changes after stoppage of PEGPH20.
    Birchenough commented, "We maintain our Outperform rating on HALO following this weekend's AACR presentation and on prospects for PEGPH20 in pancreatic CA and other cancers with high HA expression. With impressive response rate and PFS data already established, we believe that enhanced biologic understanding of PEGPH20 action further increases confidence in prospects for success in pancreatic Ca. Durable benefit following early PEGPH20 termination and lasting effects on tumor vasculature could inform new dosing strategies to optimize therapeutic index across tumor types and realize the broad potential of PEGPH20 as a platform to enhance chemotherapy efficacy. We continue to see PEGPH20 as an undervalued asset, in the context of a HALO valuation that can be supported by partnered PH20 programs like HERCEPTIN SC and MABTHERA SC."

  • assted assted Apr 19, 2015 11:18 AM Flag

    Actually your statement, "This move by management to offer to itself a special preferred stock with super voting rights, makes taking over board of VDSI virtually impossible" is incorrect, and should be amended to read, "This move by management to offer to itself a special preferred stock with super voting rights, makes taking over board of VDSI virtually impossible WITHOUT THE CONSENT OF THE BOARD". Everything is for sale at the right price. The CEO is 71 yo, owns 25% of the float, and should be ready to cash in his chips.

  • Reply to

    Those intersted in cloud-computing stocks..

    by bobbyvesco Apr 18, 2015 11:16 AM
    assted assted Apr 18, 2015 2:16 PM Flag

    Thank you for letting us know.

  • Reply to

    Near Term Catalysts?

    by drummer1517 Apr 16, 2015 12:27 PM
    assted assted Apr 16, 2015 4:21 PM Flag

    Perhaps American Society of Clinical Oncology (ASCO) meeting late next month

  • I rarely post but since there seems to be a new idiot on the board I felt the need to step up. Many of the company's officers exercised their options in March and, AS IS STANDARD OPERATING PROCDURE, sold a FRACTION of them to cover their tax liability, while holding on to the remainder.

  • assted assted Mar 30, 2015 4:05 PM Flag

    So, if they knew margins would be under pressure they should not have said anything and left themselves open to a lawsuit?

  • What per cent of VDSI's business is abroad? It seems that the stock started going south about the time the dollar really began to strengthen (which hurts profits).

  • Reply to

    target price

    by traderross2000 Mar 27, 2015 6:36 AM
    assted assted Mar 27, 2015 8:05 AM Flag

    It's there on Schwab; just a line item, no link.

  • assted by assted Mar 25, 2015 2:46 PM Flag

    It's not too early to start thinking about ASCO. Anyone know if HALO is presenting?

  • From Dec 22, 2014 SEC 8K filing. If this doesn't make your blood boil, nothing will:

    On December 19, 2014, Walter Energy, Inc. (the “Company”) entered into award agreements (each, an “Award Agreement”) with three of the Company’s current named executive officers, Walter J. Scheller, III, William G. Harvey and Earl H. Doppelt. The terms of the Award Agreements with such executive officers provide that they will receive a cash award (the “Award”), to be paid by the Company on the effective date of the Award Agreement, equal to a multiple of such executive officer’s current annual base salary. Pursuant to their respective Award Agreements, Mr. Scheller received an Award of $2,400,000 (or approximately 2.9x his current base salary), Mr. Harvey received an Award of $1,300,000 (or approximately 2.6x his current base salary) and Mr. Doppelt received an Award of $1,100,000 (or approximately 2.4x his current base salary). These awards are intended to recognize excellent individual performance and to retain the services of the executives for three full years in a challenging environment. Under the terms of each such executive officer’s Award Agreement, the executive officer will be required to repay the full gross amount of the Award to the Company if such executive officer’s employment with the Company is terminated by the executive officer without good reason (as defined in the Award Agreement), which would include a retirement by the executive officer without good reason, or by the Company for cause (as defined in the Award Agreement) prior to the third anniversary of the effective date of the Award Agreement.

  • assted assted Mar 13, 2015 8:29 AM Flag

    Yes, the bond holders are savvy investors like you. In a financially distressed company they'd rather have common stock (at the bottom of the food chain) rather than senior notes. Dream on.

  • assted assted Mar 12, 2015 4:34 PM Flag

    Notes could have been selling at 10 cents on the dollar or maybe there was no bid at all. They probably thought the chance of Walter being around in 2021 and getting the full value of the notes was remote and by getting the common shares they gained some liquidity and could sell them immediately and at least recover some $$$ of their investment. These shares hitting the market could have been responsible for the big decline the past 2 days.

5.83+0.15(+2.73%)Jul 1 4:00 PMEDT